key: cord-0750043-tlidhc0v authors: Fan, Ryan; Leasure, Audrey C.; Damsky, William; Cohen, Jeffrey M. title: The Association between Atopic Dermatitis and COVID-19 infection: A Case-Control Study in the All of Us Research Program date: 2021-12-28 journal: JAAD Int DOI: 10.1016/j.jdin.2021.12.007 sha: e34f22fb68fe9bfbfc97c54fc68fb0ed953901d4 doc_id: 750043 cord_uid: tlidhc0v Background There is incomplete understanding of the risk of coronavirus disease 2019 (COVID-19) infection in atopic dermatitis (AD) patients. Objective To evaluate the risk of COVID-19 infection in AD patients in a large, diverse cohort. Methods A case-control study of the All of Us cohort to analyze the association between AD and COVID-19. Comorbidities and risk factors were compared between cases and controls using multivariable analyses. Results In a cohort of 11,752 AD cases with 47,008 matched controls, AD patients were more likely to have a COVID-19 diagnosis (4.2% vs. 2.8%, P <0.001) compared to controls. AD remained significantly associated with COVID-19 in multivariable analysis (OR 1.29, P<0.001) after adjusting for demographic factors and comorbidities. Limitations Ascertainment of AD and COVID-19 cases using electronic health records and lack of clinical data on AD severity or therapy and COVID-19 outcomes. Conclusions AD is associated with increased odds of COVID-19 infection even after controlling for common comorbidities. Objective 37 To evaluate the risk of COVID-19 infection in AD patients in a large, diverse cohort. 38 A case-control study of the All of Us cohort to analyze the association between AD and 40 COVID-19. Comorbidities and risk factors were compared between cases and controls 41 using multivariable analyses. 42 In a cohort of 11,752 AD cases with 47,008 matched controls, AD patients were more 44 likely to have a COVID-19 diagnosis (4.2% vs. 2.8%, P <0.001) compared to controls. 45 AD remained significantly associated with COVID-19 in multivariable analysis (OR 1.29, 46 P<0.001) after adjusting for demographic factors and comorbidities. 47 Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disorders, and there is uncertainty regarding the risk of infection with SARS-CoV-2, the causative 66 virus of coronavirus disease 2019 (COVID- 19) , in AD patients. The pathophysiology of 67 AD is complex and multifactorial, though it is known to involve immune dysregulation 68 and activity of Th2 cytokines such as IL-4 and IL-13. 1 after adjusting for demographic factors and comorbidities such as BMI, hypertension, 121 hyperlipidemia, type II DM, and autoimmune disease ( Table 2 ). In a sensitivity analysis, 122 we calculated E-values to measure potential residual confounding and found that a 123 confounder would need to have an OR of 1.9 to fully explain the association between 124 AD and COVID-19. 10 125 126 Among the All of Us cohort, we found individuals with AD had a 29% increase in odds of 128 having COVID-19 infection. This large-scale study provides an additional piece of 129 evidence demonstrating increased incidence of COVID-19 among AD patients, even after 130 controlling for common comorbidities and known COVID-19 risk factors such as 131 hypertension and type II DM. Our findings confirm previously identified associations 132 J o u r n a l P r e -p r o o f between AD and various comorbidities including hypertension, type II DM, sleep apnea, 133 cardiovascular disease, malignancy, and autoimmune disease, among others. 11-13 Many 134 of these AD comorbidities have also been well-documented as significant risk factors for 135 COVD-19 infection, and risk factors for severe infection with poor outcomes in 136 particular. 14-16 Although our results were attenuated slightly in multivariable analysis after 137 considering these potential confounding factors, the relationship between AD and COVID-138 19 remained statistically significant. 139 There are limited studies investigating COVID-19 infection in AD patients ( which was similar to the findings of our study. This study also found a slightly lower risk 145 of COVID-19 infection in AD patients treated by dupilumab (IRR 0.66, 95% CI 0.52-0.83). 5 146 In contrast, a cross-sectional study looking at 5,387 patients with AD tested for COVID-147 19 found a positive test rate of 2.95%, which was a lower infection rate than non-AD 148 patients (3.66%, P = 0.0063), though this study did not control for potential confounding 149 variables. 6 Another retrospective cohort study looking specifically at 238 AD patients Atopic Dermatitis: Pathophysiology Assessing the risk of dupilumab use for atopic 191 dermatitis during the COVID-19 pandemic No evidence of increased risk for Coronavirus Disease 2019 (COVID-197 19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area -198 COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab 203 treatment-a population-based cohort study The risk of COVID-208 19 infection in patients with atopic dermatitis -a retrospective cohort study Epub 210 ahead of print CoV-2 infection in patients with atopic dermatitis: a cross-sectional study Associations between COVID-19 and skin conditions identified through 219 epidemiology and genomic studies All of Us Research Program Investigators Research Program Progress With the All of Us Research Program: 227 Opening Access for Researchers Sensitivity Analysis in Observational Research: Introducing 231 the E-Value Comorbidity and its Impact on Patients with COVID-19 Epub ahead of print COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, 259 and outcomes Risk factors for severe and critically ill COVID-19 265 patients: A review IL-13 is a driver of COVID-19 severity Atopic dermatitis is not associated with SARS-CoV-2 outcomes Epub ahead 276 of print Asthma-associated risk for 279 COVID-19 development HR of COVID-19, dupilumab vs Abbreviations: N = number, IRR = incidence rate ratio, HR = hazard ratio, MMF = 324 mycophenolate mofetil, OR = odds ratio 325